1. Clinical & Scientific Overview
Zoledronic Acid (IV Annual Bisphosphonate) & Denosumab (SC RANKL Inhibitor) (TIP-MED-000239, Reference Code [12.7]) is classified under
Osteoporosis & Bone Metabolism Medicines (Ch 12) as a Antiresorptive Nitrogen-Containing Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid—Inhibit Osteoclast Farnesyl Pyrophosphate Synthase), RANK-Ligand Monoclonal Antibody (Denosumab), and Osteoanabolic Parathyroid Hormone Fragment (Teriparatide [rhPTH 1-34]).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.7], p. 158): • Alendronate Weekly Oral Tablet (70 mg): Osteofos 70 (Cipla), Fosamax (MSD), Restofos. • Risedronate (35 mg Weekly) / Ibandronate (150 mg Monthly): Risofos 35 (Cipla), Bonmax / Flobone 150. • Zoledronic Acid Once-Yearly IV Infusion (5 mg/100 mL): Aclasta (Novartis), Zobone, Osteozol (Note: 4 mg vial is for oncology hypercalcaemia/metastases; 5 mg/100 mL is for once-yearly osteoporosis!). • Denosumab 6-Monthly Subcutaneous Injection (60 mg/mL): Prolia (Amgen/GSK), Rozel, Esentra. • Teriparatide Daily Subcutaneous Pen (20 mcg/day): Forteo (Lilly), Bonmax-PTH (Zydus), Gemtide (Alkem) — Strengths & Dosage Forms: Alendronate Oral Uncoated Tablets: 70 mg (Once Weekly) (also 10 mg daily); Zoledronic Acid IV Infusion: 5 mg/100 mL (Once Yearly); Denosumab Prefilled Syringe: 60 mg/1 mL SC (Every 6 Months); Teriparatide Multidose Pen: 20 mcg/dose SC (750 mcg/3 mL cartridge)
Alendronate Oral Uncoated Tablets: 70 mg (Once Weekly) (also 10 mg daily); Zoledronic Acid IV Infusion: 5 mg/100 mL (Once Yearly); Denosumab Prefilled Syringe: 60 mg/1 mL SC (Every 6 Months); Teriparatide Multidose Pen: 20 mcg/dose SC (750 mcg/3 mL cartridge)
3. Mechanism of Action & Pharmacodynamics
Antiresorptive Nitrogen-Containing Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid—Inhibit Osteoclast Farnesyl Pyrophosphate Synthase), RANK-Ligand Monoclonal Antibody (Denosumab), and Osteoanabolic Parathyroid Hormone Fragment (Teriparatide [rhPTH 1-34]) acting on target receptor/enzyme pathways in Osteoporosis & Bone Metabolism Medicines (Ch 12): clinical efficacy is mediated via Antiresorptive Nitrogen-Containing Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid—Inhibit Osteoclast Farnesyl Pyrophosphate Synthase), RANK-Ligand Monoclonal Antibody (Denosumab), and Osteoanabolic Parathyroid Hormone Fragment (Teriparatide [rhPTH 1-34]) for Postmenopausal osteoporosis and male senile osteoporosis (with T-score ≤ -2.5 on DEXA or history of fragility hip/vertebral/wrist fracture); glucocorticoid-induced osteoporosis (in patients taking Prednisolone ≥5–7.5 mg/day for ≥3 months)..
4. Therapeutic Indications & Evidence-Supported Uses
- Postmenopausal osteoporosis and male senile osteoporosis (with T-score ≤ -2
- 5 on DEXA or history of fragility hip/vertebral/wrist fracture)
- glucocorticoid-induced osteoporosis (in patients taking Prednisolone ≥5–7
- 5 mg/day for ≥3 months)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: • Alendronate: 70 mg Orally ONCE A WEEK (on a single fixed morning, e.g., Every Sunday at 06:00 AM)! NEVER TAKE DAILY! • Zoledronic Acid: 5 mg IV infusion over at least 15–30 minutes once a year. • Denosumab: 60 mg subcutaneously once every 6 months. • Teriparatide: 20 mcg subcutaneously once daily (in thigh or abdomen) for a maximum lifetime duration of 24 months (2 years), followed immediately by an antiresorptive (bisphosphonate/denosumab) to lock in bone gains!
Administration & Meal Timing: STRICT ALENDRONATE OESOPHAGEAL & ABSORPTION PROTOCOL: Take 70 mg ONCE WEEKLY on one fixed morning immediately upon waking on a strictly EMPTY STOMACH with a full tall glass (200–250 mL) of PLAIN TAP/FILTERED WATER ONLY (never mineral water, tea, coffee, juice, or milk). Swallow whole (never crush/chew/suck). Remain STRICTLY UPRIGHT (sitting/standing) and take NO food, drink, calcium, iron, or other morning tablets for AT LEAST 30–60 MINUTES (60 min for Ibandronate). (Zoledronate is IV yearly; Denosumab is SC q6m; Teriparatide is SC daily). | Alendronate: Early morning upon rising on the chosen weekly day (e.g., Sunday 06:00 AM).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Alendronate, Risedronate, and IV Zoledronic Acid are CONTRAINDICATED if CrCl / eGFR <35 mL/min. Denosumab (60 mg SC q6m) requires no renal dose adjustment, BUT in advanced CKD (Stage 4–5, eGFR <30 mL/min or dialysis) carries a CRITICAL BOXED RISK of severe, life-threatening hypocalcaemia — requires specialist CKD-MBD/iPTH assessment, pre-dose correction of Ca2+ & 25(OH)D, calcium + active vitamin D (calcitriol) cover, and close serum Ca2+ monitoring within 7–14 days post-dose!
Renal: Alendronate, Risedronate, and IV Zoledronic Acid are CONTRAINDICATED if CrCl / eGFR <35 mL/min. Denosumab (60 mg SC q6m) requires no renal dose adjustment, BUT in advanced CKD (Stage 4–5, eGFR <30 mL/min or dialysis) carries a CRITICAL BOXED RISK of severe, life-threatening hypocalcaemia — requires specialist CKD-MBD/iPTH assessment, pre-dose correction of Ca2+ & 25(OH)D, calcium + active vitamin D (calcitriol) cover, and close serum Ca2+ monitoring within 7–14 days post-dose!
Renal: Alendronate, Risedronate, and IV Zoledronic Acid are CONTRAINDICATED if CrCl / eGFR <35 mL/min. Denosumab (60 mg SC q6m) requires no renal dose adjustment, BUT in advanced CKD (Stage 4–5, eGFR <30 mL/min or dialysis) carries a CRITICAL BOXED RISK of severe, life-threatening hypocalcaemia — requires specialist CKD-MBD/iPTH assessment, pre-dose correction of Ca2+ & 25(OH)D, calcium + active vitamin D (calcitriol) cover, and close serum Ca2+ monitoring within 7–14 days post-dose!
7. Contraindications, Precautions & High-Risk Warnings
- SEVERE HYPOCALCAEMIA IN ADVANCED CKD (eGFR <30 mL/min / G4–G5D): High risk of life-threatening, prolonged symptomatic hypocalcaemia (tetany, laryngospasm, QT prolongation, seizures). Correct Vitamin D and serum calcium BEFORE injection, ensure specialist CKD-MBD evaluation, supplement Calcium + Calcitriol, and monitor serum calcium within 7–14 days post-dose.
Key Clinical Precautions: Renal: Alendronate, Risedronate, and IV Zoledronic Acid are CONTRAINDICATED if CrCl / eGFR <35 mL/min. Denosumab (60 mg SC q6m) requires no renal dose adjustment, BUT in advanced CKD (Stage 4–5, eGFR <30 mL/min or dialysis) carries a CRITICAL BOXED RISK of severe, life-threatening hypocalcaemia — requires specialist CKD-MBD/iPTH assessment, pre-dose correction of Ca2+ & 25(OH)D, calcium + active vitamin D (calcitriol) cover, and close serum Ca2+ monitoring within 7–14 days post-dose!
8. Adverse Effects Profile
- • Alendronate: Epigastric pain, heartburn, dysphagia, musculoskeletal bone/joint/muscle ache. • Zoledronic Acid IV: Acute Phase Reaction in 30–40% of patients after the 1st annual infusion (fever, chills, myalgia, arthralgia, bone pain starting 12–24 hours post-infusion and lasting 2–3 days—prevented by giving Paracetamol 650 mg TDS for 3 days starting at the infusion!). • Teriparatide: Transient orthostatic dizziness/leg cramps within 1–4 hours of injection, mild transient hypercalcaemia.
- Corrosive Chemical Oesophagitis, Deep Oesophageal Ulcers, Perforation, and Stricture (from Alendronate if taken with little water or followed by lying down!), Medication-Related Osteonecrosis of the Jaw (MRONJ—exposed non-healing jaw bone after tooth extraction with bisphosphonates/denosumab!), Atypical Subtrochanteric / Diaphyseal Femoral Shaft Fractures (with >5 years continuous therapy—heralded by prodromal dull aching thigh or groin pain!), Severe Hypocalcaemia (especially with Denosumab in CKD!).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Oral Bisphosphonates (Alendronate): Food, coffee, orange juice, mineral water, Calcium, Iron, Magnesium, and Antacids reduce oral absorption (already only 0
- 6% when fasting!) down to ZERO! 2
- NSAIDs (Diclofenac, Ibuprofen, Naproxen) & Aspirin: Synergistic risk of severe upper GI ulceration with oral Alendronate, and acute renal tubular necrosis with IV Zoledronic Acid!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Walk every patient step-by-step through the 4-Point Alendronate Upright Rule (Plain water 250 mL, empty stomach, sit/stand upright 30–60 min, Calcium at lunchtime). 2. If the patient also takes early-morning Levothyroxine (Thyronorm), do NOT take Alendronate and Levothyroxine together on Sunday morning—either take Alendronate at 06:00 AM and Levothyroxine 45 minutes later, or take Levothyroxine at bedtime on Saturday night! 3. Dental Extraction Precaution: Advise completing any needed tooth extractions before starting bisphosphonates/denosumab, maintaining good dental hygiene, and informing the dentist. 4. Teriparatide Cold-Chain Rule: Keep the Bonmax-PTH / Forteo pen refrigerated (2°C–8°C) at all times—take it out, inject in the thigh while seated (to avoid dizziness), and return the pen to the refrigerator immediately!
- Meal & Clock Timing Instruction: STRICT ALENDRONATE OESOPHAGEAL & ABSORPTION PROTOCOL: Take 70 mg ONCE WEEKLY on one fixed morning immediately upon waking on a strictly EMPTY STOMACH with a full tall glass (200–250 mL) of PLAIN TAP/FILTERED WATER ONLY (never mineral water, tea, coffee, juice, or milk). Swallow whole (never crush/chew/suck). Remain STRICTLY UPRIGHT (sitting/standing) and take NO food, drink, calcium, iron, or other morning tablets for AT LEAST 30–60 MINUTES (60 min for Ibandronate). (Zoledronate is IV yearly; Denosumab is SC q6m; Teriparatide is SC daily). (Alendronate: Early morning upon rising on the chosen weekly day (e.g., Sunday 06:00 AM).)
- Missed Dose Protocol: Alendronate 70 mg Weekly Missed-Dose Rule: If the Sunday morning tablet is forgotten, take 1 tablet on Monday morning immediately upon waking on an empty stomach, and then return to the normal Sunday schedule the next week—NEVER take two 70 mg tablets on the same day or in the same week!
- Geriatric Dispensing Pearl: Verify that any bedridden elderly CGHS patient, or a patient with dementia, stroke dysphagia, severe GERD, or CrCl <35 mL/min is NOT prescribed oral Alendronate (switch to parenteral Zoledronic Acid [if CrCl ≥35] or Denosumab with calcium/D3 cover!).
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.7] (p. 158)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.18]-C166 Risedronate Sodium — Nitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyro
- [12.18] Alendronate Sodium & Risedronate (Weekly Oral Bisphosphonates) — Nitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyro
- [12.19] Teriparatide (Recombinant PTH 1-34 Osteoanabolic Injection) — Recombinant Human Parathyroid Hormone Fragment [rhPTH(1-34)] (Ost
- [12.7]-C156 Denosumab (60 mg SC q6m) — Antiresorptive Nitrogen-Containing Bisphosphonates (Alendronate,